Patient characteristics
. | Number of patients . |
---|---|
Sex | |
Male | 5 (42%) |
Female | 7 (58%) |
Age, median (range), y | 66 (48-79) |
Background bowel function | |
Normal | 5 (42%) |
Lifelong intermittent loose stool | 3 (25%) |
Other GI history (not diarrhea) | 4 (33%) |
Time to deterioration of bowel function following lenalidomide commencement, median (range), mo | 6 (1-15) |
Dose of lenalidomide | |
25 mg | 5 (41%) |
10-15 mg | 7 (58%) |
Symptoms | |
Diarrhea* | 12 (100%) |
Urgency | 11 (92%) |
Fecal incontinence | 7 (58%) |
Abdominal cramps | 5 (42%) |
. | Number of patients . |
---|---|
Sex | |
Male | 5 (42%) |
Female | 7 (58%) |
Age, median (range), y | 66 (48-79) |
Background bowel function | |
Normal | 5 (42%) |
Lifelong intermittent loose stool | 3 (25%) |
Other GI history (not diarrhea) | 4 (33%) |
Time to deterioration of bowel function following lenalidomide commencement, median (range), mo | 6 (1-15) |
Dose of lenalidomide | |
25 mg | 5 (41%) |
10-15 mg | 7 (58%) |
Symptoms | |
Diarrhea* | 12 (100%) |
Urgency | 11 (92%) |
Fecal incontinence | 7 (58%) |
Abdominal cramps | 5 (42%) |
Data are presented as n (%) of patients unless indicated otherwise.
Defined by Bristol Stool Chart (BSC) score 6 or 7. Median stool frequency: 6 episodes per day (range, 1-10).